
|Articles|September 1, 2001
Grateful Med soon to be dead - long live the NLM Gateway
Better, more consistent public access to databases now available per request of taxpayers
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
KT-621 Produces 98% STAT6 Degradation in AD Patients
3
DeepSeek-R1 Outperforms ChatGPT-4o in Urticaria Clinical Queries
4
Abeona Initiates First Commercial Treatment of Zevaskyn for RDEB
5



















